
Orna Therapeutics
Founded Year
2019Stage
Series B | AliveTotal Raised
$321MValuation
$0000Last Raised
$221M | 3 yrs agoMosaic Score The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.
+96 points in the past 30 days
About Orna Therapeutics
Orna Therapeutics is a biotechnology company involved in the development of circular RNA therapeutics and lipid nanoparticle (LNP) delivery systems. The company's offerings include engineered circular RNA (oRNA) medicines meant to treat various diseases and LNP technologies that deliver these RNA therapies to targeted sites in the body. Orna Therapeutics serves sectors related to oncology, autoimmune disease treatment, and genetic disorders. It was founded in 2019 and is based in Cambridge, Massachusetts.
Loading...
Loading...
Expert Collections containing Orna Therapeutics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Orna Therapeutics is included in 1 Expert Collection, including Unicorns- Billion Dollar Startups.
Unicorns- Billion Dollar Startups
1,276 items
Orna Therapeutics Patents
Orna Therapeutics has filed 17 patents.
The 3 most popular patent topics include:
- molecular biology
- rna
- biotechnology

Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
11/3/2023 | 12/31/2024 | Molecular biology, RNA, Biotechnology, Gene expression, Genetics | Grant |
Application Date | 11/3/2023 |
---|---|
Grant Date | 12/31/2024 |
Title | |
Related Topics | Molecular biology, RNA, Biotechnology, Gene expression, Genetics |
Status | Grant |
Latest Orna Therapeutics News
Jun 4, 2025
米Orna Therapeutics(オルナ・セラピューティクス)社は2025年5月15日、米遺伝子細胞治療学会(ASGCT)で、他家抗CD19 in vivoキメラ抗原受容体(CAR)療法(CD19 in vivo CAR)の最新データを発表した。同社が保有する環状RNAの基盤技術「oRNA」と脂質ナノ粒子(LNP)を用いた免疫システムへの送達技術「panCAR」により創出されたCD19 in vivo CARが、自己免疫疾患を適応候補として実施した前臨床試験で、ヒト化マウスモデル、非ヒト霊長類(NHP)モデルに強力かつ持続的なB細胞除去効果を示した。同社は2026年の臨床入りを目指すとしている。
Orna Therapeutics Frequently Asked Questions (FAQ)
When was Orna Therapeutics founded?
Orna Therapeutics was founded in 2019.
Where is Orna Therapeutics's headquarters?
Orna Therapeutics's headquarters is located at 620 Memorial Drive, Cambridge.
What is Orna Therapeutics's latest funding round?
Orna Therapeutics's latest funding round is Series B.
How much did Orna Therapeutics raise?
Orna Therapeutics raised a total of $321M.
Who are the investors of Orna Therapeutics?
Investors of Orna Therapeutics include Merck & Co, MPM BioImpact, F2 Ventures, Kite Pharma, Pagsgroup and 6 more.
Who are Orna Therapeutics's competitors?
Competitors of Orna Therapeutics include Harness Therapeutics, Laronde, VaxEquity, Strand Therapeutics, Translate Bio and 7 more.
Loading...
Compare Orna Therapeutics to Competitors

Strand Therapeutics focuses on the development of programmable, long-acting mRNA therapeutics within the biotechnology sector. The company offers a platform for creating mRNA drugs that are designed to deliver precise, multi-functional, and potentially curative treatments by programming logic-based circuits into mRNA to control protein expression in targeted cells. Strand Therapeutics' products are primarily aimed at improving treatment options for cancer and other life-threatening diseases. It was founded in 2017 and is based in Boston, Massachusetts.
VaxEquity develops RNA-based therapeutics and vaccines designed to meet medical needs. It specializes in amplifying the impact of RNA vaccines and therapeutics by using its self-amplifying RNA platform and provides better protein expression. The company was founded in 2020 and is based in Cambridge, U.K.
Harness Therapeutics operates as a biotechnology company. It focuses on developing disease-modifying therapeutics for neurodegenerative diseases. The company specializes in messenger ribonucleic acid (mRNA)-targeted oligonucleotide-based methodologies to increase protein levels in a controlled manner. It aims to transform the treatment of conditions such as Alzheimer's, Parkinson's, and Huntington's disease. Harness Therapeutics primarily serves the healthcare sector. It was formerly known as Transine Therapeutics. Harness Therapeutics was founded in 2018 and is based in Cambridge, United Kingdom.

Sapreme Technologies is a preclinical-stage biotech company focused on developing RNA therapeutics for genetically driven diseases. The company's main offerings include endosomal escape technology that facilitates the delivery of large molecules such as antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) to intracellular targets in various tissues, including the liver, muscle, heart, kidney, and brain. Sapreme's technology platform aims to improve receptor-targeted delivery and endosomal release of therapeutics in conditions like neuromuscular, renal, and cardiometabolic diseases. It was founded in 2016 and is based in Utrecht, Netherlands.
Cook MyoSite focuses on muscle cell technology and regenerative medicine. The company provides primary human skeletal muscle cells and laboratory research services, including custom manufacturing and analysis for research purposes. Cook MyoSite serves the medical research and clinical development sectors. It was founded in 2002 and is based in Pittsburgh, Pennsylvania.

Versameb is a biotechnology company that focuses on the discovery and development of RNA-based drugs. The company provides solutions for modulating protein expression and influencing therapeutic targets using a molecular construct. Versameb's VERSagile technology platform supports the application of functional RNA in different disease contexts to expand the use of RNA therapeutics. It was founded in 2017 and is based in Basel, Switzerland.
Loading...